News

CAR T-Cell Therapy Market to Surge at 40.2% CAGR Over the Next Five Years
Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...
Cartesian: Autoimmune Cell Therapy Excites, But Reality Bites
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
Targeted Oncology2h
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...
Targeted Oncology9h
Dr Voorhees Highlights Durability of Cilta-Cel in Myeloma
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma.